Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

15th International Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2013) /
‘Go-Go’ CLL patients: a look towards the future

9th - 11th Sep 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.11.13
Views: 3470

Professor Clemens Wendtner - Klinikum Schwabing, Munich, Germany

Professor Wendtner gives an overview of the latest FCR vs. FC results in terms of PFS and OS, and outlines how these can be predicted in peripheral blood.  However, toxicity issues and secondary malignancies need to be managed with FCR, and ideally future concepts will address this. 

Indeed, the phase II trial in ‘go-go’ patients with bendamustine plus rituximab is outlined, with fewer adverse events observed vs. FCR.

Also, results of a phase III trial of bendamustine plus rituximab vs. FCR in ‘go-go’ patients will soon be announced. Professor Wendtner also mentions on-going studies in this patient group with lenalidomide.

Finally, future clinical studies are outlined, eg, CLL13, CLL3001/CLLR1 and CLL14, as are the numerous newer treatments being explored, eg, ibrutinib, GA-101 and ABT-199.


Content taken from a Mundipharma sponsored satellite symposium at iwCLL 2013 as part of the official programme.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation